An Interview with Chief Technology Officer (CTO) John Cray

NORTH AURORA, Ill., February 28, 2023 (Newswire.com) - Mental Health Technologies (MHT) offers a rapidly growing cloud-based platform primary care physicians and mental health professionals use to screen and test for mental health disorders, including depression and substance abuse. MHT helps providers identify areas where their patients are struggling and refers them to the proper behavioral healthcare professional.

In a recent interview, MHT's CTO, John Cray, talks about how their technology is different and discusses the company's newest innovation:

What is SmarTest?

SmarTest is a tool that uses intelligence and historical data to define when—and how—a patient should be tested for various mental health conditions. It can base its decisions on patient information, such as age, gender, or other demographics. Every clinic or provider group can define its own rules for how SmarTest works.

A clinician may test patients on a particular treatment regimen for depression every three months, but those who indicate severe depression may require more frequent measurement. A primary care practice may test all patients once per year for certain conditions but use the assessment results to automate the referral of certain patients to mental health providers.

How do you work with evolving needs of clients?

Our company understands that we need to be receptive to feedback so that we can maximize our value and help in any way we can. We continuously meet with our current and prospective clients to plan what we do next to make the most of our services.

For example, based on the need to get new tests into the system as quickly as possible, we developed a wizard that allows us to create a new test in a matter of minutes. We can very quickly enhance clinic-specific or standardized tests. This level of flexibility is unique to us, as well.

We also recently released a new feature that can automatically route them to a webpage that is optimized to help them. If a patient indicates suicidality, they can be directed immediately to the 988 suicide lifeline page. Or if the patient answers above a certain score depression level, we can route them to a page describing advanced treatment options for them.

How are you measuring MHT's success?

MHT saw a 20% growth rate in 2022. In the month of January 2023 alone, we grew an additional 20%. We use our data to measure our own success and drive our focus. And we are also working to use this data to provide valuable analytics to our customers. 

Clinics can compare their own results to benchmark data across the industry by whatever metric they desire. MHT can report on whether a practice's patients are improving faster or slower than similar patients across the country. The data itself is a goldmine of information for decision-making. 

Contact Information:
Ernie Wallerstein
CEO
[email protected]
6402400323

John Cray
CTO
[email protected]
630.544.8958

Bill Leonhard
VP of Sales
[email protected]
6308038582

Paige Pontrelli
Business Development Manager
[email protected]
6305469816


Original Source: MHT Delivers New Technology for Measuring and Improving Mental Wellness

ForCast Orthopedics Receives Qualified Infection Disease Product (QIDP) Designation from FDA for the Treatment of Periprosthetic Joint Infection (PJI)

DENVER, February 28, 2023 (Newswire.com) - ForCast Orthopedics today announced that the US Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation for ForCast's lead program, FC001, for the treatment of periprosthetic joint infection (PJI).

PJI is a rare but serious complication of joint replacement procedures that can threaten the function of the joint, the preservation of the limb and even the life of the patient. PJI is challenging to treat because the infecting bacteria adhere to the prothesis and form a protective biofilm that can be resistant to standard systemic antibiotics.

FC001 is being developed to address these challenges by delivering a targeted antibiotic therapy directly into the infected joint using ForCast's proprietary technology.

QIDP designation, provided under the Generating Antibiotic Incentives Now Act (GAIN Act), offers certain incentives for the development of new antifungal and antibacterial drugs that treat serious or life-threatening infections. These incentives include Fast Track designation, priority review, and additional market exclusivity if the product is approved by the FDA.

"We are very pleased to receive QIDP designation from the FDA," said Peter Noymer, PhD, Executive Chairman and CEO of ForCast Orthopedics. "This represents an important milestone for the company as we progress our lead product through development and toward commercialization."

"This is an exciting step forward for ForCast," added Jared Foran, MD, Chief Scientific Officer and co-founder of ForCast Orthopedics, "and one that validates our commitment to making better therapies available sooner for PJI patients."

About ForCast Orthopedics

ForCast is a development-stage company with a focus on pioneering the treatment of periprosthetic joint infection (PJI) with targeted antibiotic therapy. Our mission is to modernize the standard of care for PJI and improve the quality of life for the growing population of joint replacement patients.

Contact Information:
Peter Noymer
Executive Chairman and CEO
[email protected]


Original Source: ForCast Orthopedics Receives QIDP Designation From FDA

PARIS, FRANCE, February 28, 2023 (Newswire.com) - On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel digital biomarkers for the self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.

gMG and NMOSD are chronic severe diseases in which progression is complex and critical to monitor. The course of NMOSD is driven by episodes of severe, sequential relapses leading to the accrual of permanent disability, while gMG is characterized by a heterogeneous collection of symptoms (including fatigue and muscle group weakness) which fluctuate over time.

Currently, no objective measurement tools exist to allow gMG and NMOSD patients to track their symptoms over time. Digital biomarkers are patient-generated physiological and behavioral measures that are collected from digital devices like smartphones and processed by algorithms. If clinically validated, these measures could provide data to improve the remote monitoring of disease symptoms.

"We believe that empowering patients through real-time digital data sharing could strengthen communication between patients and healthcare professionals, and may enable more informed disease management decisions," said Dr. Guido Sabatella, Global Medical Lead in Neurology at Alexion. 

"Easy-to-use digital tools have the potential to generate reliable and objective data to better understand the real impact of the disease on patients' lives and also have the potential to demonstrate the benefits of novel therapies to keep disease under control," explains Matthieu Lamy, Ad Scientiam's President.

Scoping phases have been conducted for both programs to identify clinically meaningful digital biomarkers to monitor patients living with NMOSD or gMG. Ongoing research will inform the development of a digital medical device intended to be used by patients as a self-assessment tool.

"International, multicenter, comparative studies against clinical gold standards, such as the Quantitative Myasthenia Gravis score and assessments of visual function, ambulation and dexterity in NMOSD, will be deployed to confirm the clinical relevance of selected digital biomarkers," according to Dr. Saad Zinaï, Ad Scientiam's Chief Medical Officer.

About Ad Scientiam 

We strongly believe that continuously monitoring the progression of severe and disabling diseases in real life is crucial for delivering better care. 

To achieve this, we create and clinically validate digital biomarkers that make visible these previously undetectable changes. These biomarkers are developed using data collected through smartphones and transformed using proprietary algorithms.

Hospital institutions such as the Paris Brain Institute (ICM) and pharmaceutical companies, including Biogen, Janssen, Roche, Pfizer, Vertex, and Novartis, trust us. In 2019, we launched MSCopilot®, the first CE-marked software medical device for the self-assessment of patients with multiple sclerosis. We are currently validating new devices in neuroscience, rare diseases, and mental disorders. Ad Scientiam is ISO 13485 certified.

Check our LinkedIn and Facebook page, or visit adscientiam.com.

Press contact: [email protected]

Contact Information:
Saad Zinaï
Chief Medical Officer
[email protected]
+33768008666

Matthieu Lamy
President
[email protected]
+33768008666
Related Files
FEB2023_Ad Scientiam digital biomarkers PR_Final_for Newswire.pdf



Original Source: Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases

FRISCO, Texas, February 27, 2023 (Newswire.com) - Economic Transformation Technologies (ETT), a leading provider of on-premise or cloud-based solutions for healthcare, has announced the launch of its Intelligent Healthcare Interoperability Platform as a Service (PaaS) solution. The new solution is designed to accelerate the seamless integration of disparate data sources and applications with an AI-enabled solution to generate actionable information for clinical decision-making, population health management, quality-driven health outcomes, and value-based care. ETT's Intelligent Interoperability PaaS provides an affordable and agile solution for providers, health systems, and patients to allow an AI-enabled comprehensive solution for patient-centric clinical care as well as for population health management within a single unified platform.

"We're thrilled to introduce our new PaaS Intelligent Interoperability Platform solution to the healthcare industry, through our wholly owned subsidiary BioDatAi," said Chris Condon, ETT, Executive Chairman & CEO. 

"Our solution offers a streamlined and efficient way for healthcare organizations to integrate their data sources, providing them with a comprehensive view of patient information and improving their ability to make informed decisions about patient care," said Kelly Cook, BioDatAi, CEO. 

The PaaS intelligent interoperability solution is built on top of ETT's industry-leading cloud infrastructure, providing a highly scalable and secure environment for healthcare data management.

"ETT's innovative intelligent interoperable healthcare Platform as a Service provides an affordable and accessible solution to fulfill the promise of interoperability to truly help transform health systems," said Antonio Fernandez, Advisor for BioDatAi and ETT. 

Greg Carson, CRO of, BioDatAi shares that, "ETT excels in its ability to provide client-centered agile and cost-effective interoperable approaches for sustainable solutions across a broad spectrum of healthcare environments." 

It allows the fast and agile integration of data from various sources, including electronic health records (EHRs), claims, medical imaging systems, Internet of Things (IoT), Internet of HealthCare wearable devices, Health Information Exchanges (HIEs), and other sources and applications. By providing access to this solution based on a "Platform as a Service Model'', ETT provides affordable and cost-effective access to comprehensive and actionable health information for providers, patients, and health systems.

ETT's Chief Technology Officer (CTO) David Smith enthusiastically states that "ETT's multi-level secure platform not only provides real-time integration of systems and data but allows clients to draw upon embedded services such as advanced Artificial Intelligence (AI), Machine Learning (ML), and Data Science."

 "It provides companies with the ability to seamlessly integrate and manage their data sources in a single, unified platform, enabling them to provide more efficiency and effectiveness," added John Czelusniak, ETT's Chief Growth Officer.

BioDatAi: 

BioDatAi Inc. is a wholly owned subsidiary of ETT that offers a secure and interoperable platform aimed at simplifying the development of cutting-edge applications that provide value to clinical and business aspects of Healthcare and national policies. For more information, visit www.biodatai.com and www.ettworld.com

Contact:

John Czelusniak | ETT  | [email protected]

Contact Information:
John Czelusniak
Chief Growth Officer
[email protected]
3052836336


Original Source: ETT's PaaS: The Intelligent Cure for Healthcare's Interoperability

SANTA MONICA, Calif., February 27, 2023 (Newswire.com) - L-Nutra Inc., a leading nutrition technology company that pioneers the discovery, design, and commercialization of novel nutrition programs that impact cellular rejuvenation and support healthy aging, announced the results of a first-ever study evaluating the impact of its Fasting Mimicking Diet (ProLon®) on skin hydration, texture, and psychological well-being in women. 

The study, which was published in the Journal of Clinical Medicine, is the first randomized controlled trial demonstrating the efficacy of a five-day Fasting Mimicking Diet (FMD) Nutrition protocol on enhancing skin quality, smoothness, hydration, and key components of psychological well-being. Skin health and mental wellbeing are common concerns among women, and this research provides compelling evidence for the effectiveness of FMD Nutrition in improving overall health. 

"This study demonstrates the holistic and systemic impact of the Fasting Mimicking Technology affecting cellular rejuvenation from as deep as the inner organ systems to the surface tissue like skin. Together with other published FMD studies in diabetes and cancer, this research further validates that FMD Nutrition is a powerful tool in Lifestyle medicine to improve overall health," said William Hsu, MD, Chief Medical Officer of L-Nutra Inc. 

The researchers recruited 45 female participants, ranging from 35 to 60 years old. The group that used the FMD Nutrition five days per month for three consecutive months had significant improvements in skin hydration as measured by Corneometer, as well as maintenance of skin texture, smoothness and tone evenness, compared to individuals in the standard of care group. Participants also reported significant improvements in feelings of happiness, confidence and empowerment to take control of their health, as well as optimism about the future. 

 "This successful clinical trial is another testimony for the rejuvenative power of the Fasting Mimicking Diet. Our goal is to help everyone live a long and healthy life by keeping our biological age younger than our chronological age. Through this trial, we have demonstrated what many of our ProLon® consumers have reported for years, a healthier looking, glowing skin, which helps people around the world feel happy and confident about their lives," said Joseph Antoun, M.D., Ph.D., CEO and Chairman of L-Nutra Inc.  

About L-Nutra Inc. 

L-Nutra Inc. is a company that is focused on discovering, designing, and commercializing novel nutritional programs with the goal of improving human health and adding more life to human life. Its current commercial products are aimed at promoting wellness and healthy aging. ProLon® is the company's flagship product, which is the first and only clinically tested 5-day FMD Nutrition program designed to allow the body to enter a fasting state while still consuming nutrient-dense foods. L-Nutra also offers ProLon Reset™, a 1-day FMD Nutrition kit, and ProLon Intermittent Fasting Bar®, a nutrition bar designed and clinically tested to support intermittent fasting. The company's Nutrition for Longevity® program offers science-backed, chef-curated meals formulated to address the nutritional deficiencies in commercially grown produce. For more information, visit https://l-nutra.com/.

Contact Information:
William Hsu
Chief Medical Officer
[email protected]
6176554394


Original Source: L-Nutra Reports First-Ever Study Showing ProLon® Improves Skin Health, Happiness, and Confidence